TNF and aspergillosis: As such, treatment with tumor necrosis factor alpha (TNF‐α) blocking agents increases the risk of tuberculosis, Pneumocystis jirovecii infection and aspergillosis, and meta-analyses have reported increased risk for serious infectious complications [53,54].